By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



9 Ha’Ta’asiya Street

Ra’anana    4365007  Israel
Phone: 972-9-7707600 Fax: n/a


UroGen Pharma (“UroGen” or the “Company”) is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The lead drug candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer and low-grade upper tract urothelial carcinoma, or UTUC. In addition, UroGen is developing an additional clinical-stage drug candidate, Vesimune, for the treatment of high-grade non-muscle invasive bladder cancer. The company has recently licensed BotuGel for the treatment of overactive bladder and interstitial cystitis, to Allergan for further development.




CEO: Ron Bentsur

CFO: Gary Titus


Please click here for clinical trial information.

Key Statistics

Ownership: Private

Web Site: UroGen


Company News
UroGen Strengthens Management Team With The Appointment Of Paul Chu As Vice President Of Business Development 9/6/2017 8:57:18 AM
UroGen Receives FDA Fast Track Designation For Mitogel For The Treatment Of Upper Tract Urothelial Carcinoma (UTUC) 8/29/2017 10:41:08 AM
UroGen Reports Second Quarter 2017 Financial Results And Recent Corporate Developments 8/15/2017 7:53:35 AM
UroGen Pharma To Ring The Nasdaq Stock Market Opening Bell 6/2/2017 8:31:27 AM
UroGen Appoints Fred E. Cohen, MD, To Its Board Of Directors 5/16/2017 10:39:03 AM
UroGen Announces Closing Of Initial Public Offering And Exercise Of Underwriters’ Option 5/10/2017 10:10:03 AM
UroGen Announces Pricing Of Initial Public Offering 5/4/2017 11:42:49 AM
UroGen Welcomes New Board Member Kate Falberg 4/24/2017 11:22:35 AM
UroGen Announces Enrollment Of First Patient In Phase III Clinical Trial Of Mitogel For Treatment Of Low-Grade Upper Tract Urothelial Carcinoma 4/3/2017 1:40:56 PM
UroGen Announces FDA Acceptance Of Investigational New Drug Application For Mitogel, A Novel Sustained Release Formulation Of Mitomycin C, For The Treatment Of Low-Grade Upper Tract Urothelial Carcinoma 12/12/2016 7:53:34 AM